# Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy in Humans

> **NCT06411366** · PHASE1 · COMPLETED · sponsor: **Minicircle** · enrollment: 43 (actual)

## Conditions studied

- Frailty
- Aging

## Interventions

- **GENETIC:** Follistatin plasmid

## Key facts

- **NCT ID:** NCT06411366
- **Lead sponsor:** Minicircle
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-18
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411366, "Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy in Humans". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06411366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*